1. Home
  2. SOHU vs IKT Comparison

SOHU vs IKT Comparison

Compare SOHU & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

SELL

Current Price

$12.54

Market Cap

324.6M

Sector

Technology

ML Signal

SELL

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.85

Market Cap

274.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
IKT
Founded
1996
2008
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
324.6M
274.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
SOHU
IKT
Price
$12.54
$1.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
★ $19.50
$6.00
AVG Volume (30 Days)
84.9K
★ 542.5K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 57.76
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.46
$33.33
P/E Ratio
$1.16
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$1.33
52 Week High
$17.30
$2.61

Technical Indicators

Market Signals
Indicator
SOHU
IKT
Relative Strength Index (RSI) 39.14 31.17
Support Level $12.41 $1.59
Resistance Level $13.71 $1.91
Average True Range (ATR) 0.36 0.10
MACD -0.01 -0.02
Stochastic Oscillator 25.51 13.89

Price Performance

Historical Comparison
SOHU
IKT

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: